test-section

Clinical Trials

A Study of OKI-179 in Patients
With Solid Tumors

Press Releases

July 23, 2019

OnKure Executes License and Option Agreement with KDAc Therapeutics

June 11, 2019

OnKure and CU Cancer Center announce first patient enrolled in clinical trial of OKI-179

May 05, 2019

OnKure Announces FDA IND Regulatory Clearance to Start Phase 1 Trials for OKI-179

May 02, 2018

OnKure Close $7M Series A Financing to Support Development of Epigenetics Drug

our-philosophy-is

There are several lines of evidence suggesting the important role of epigenetics in cancer, including the fact that all cancers show epigenetic change, and most cancer mutations affect the epigenome.

Andrew Feinberg from the Johns Hopkins School of Medicine Center for Epigenetics in Baltimore, Maryland